| Tchem | Signal transducer and activator of transcription 5A |
Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Mediates cellular responses to ERBB4. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the GAS element and activates PRL-induced transcription. Regulates the expression of milk proteins during lactation.
The protein encoded by this gene is a member of the STAT family of transcription factors. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein is activated by, and mediates the responses of many cell ligands, such as IL2, IL3, IL7 GM-CSF, erythropoietin, thrombopoietin, and different growth hormones. Activation of this protein in myeloma and lymphoma associated with a TEL/JAK2 gene fusion is independent of cell stimulus and has been shown to be essential for tumorigenesis. The mouse counterpart of this gene is found to induce the expression of BCL2L1/BCL-X(L), which suggests the antiapoptotic function of this gene in cells. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Dec 2013]
The protein encoded by this gene is a member of the STAT family of transcription factors. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein is activated by, and mediates the responses of many cell ligands, such as IL2, IL3, IL7 GM-CSF, erythropoietin, thrombopoietin, and different growth hormones. Activation of this protein in myeloma and lymphoma associated with a TEL/JAK2 gene fusion is independent of cell stimulus and has been shown to be essential for tumorigenesis. The mouse counterpart of this gene is found to induce the expression of BCL2L1/BCL-X(L), which suggests the antiapoptotic function of this gene in cells. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Dec 2013]
Comments
Property Summary
| Ligand Count | 4 |
| NCBI Gene PubMed Count | 308 |
| PubMed Score | 960.22 |
| PubTator Score | 988.13 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Adenocarcinoma | 122 | 0.0 | 0.0 |
| Breast Neoplasms | 445 | 0.0 | 0.0 |
| Carcinoma | 11493 | 0.0 | 0.5 |
| Carcinoma, Ductal | 4 | 0.0 | 0.0 |
| Carcinoma, Intraductal, Noninfiltrating | 5 | 0.0 | 0.0 |
| Carcinoma, Lobular | 6 | 0.0 | 0.0 |
| Lung Neoplasms | 232 | 0.0 | 0.0 |
| Mammary Neoplasms, Animal | 136 | 0.0 | 0.0 |
| Mammary Neoplasms, Experimental | 154 | 0.0 | 0.0 |
| Myocardial Ischemia | 169 | 0.0 | 0.0 |
| Precancerous Conditions | 80 | 0.0 | 0.0 |
| Disease | Target Count |
|---|---|
| Animal Mammary Neoplasms | 136 |
| Ductal Carcinoma | 4 |
| Mammary Neoplasms | 425 |
| Noninfiltrating Intraductal Carcinoma | 5 |
| Disease | Target Count | P-value |
|---|---|---|
| malignant mesothelioma | 3232 | 2.0e-06 |
| osteosarcoma | 7950 | 3.6e-05 |
| group 4 medulloblastoma | 1855 | 8.8e-05 |
| invasive ductal carcinoma | 2951 | 2.5e-04 |
| ductal carcinoma in situ | 1745 | 2.6e-04 |
| lung cancer | 4740 | 6.1e-04 |
| Disease | log2 FC | p |
|---|---|---|
| ductal carcinoma in situ | -1.400 | 2.6e-04 |
| group 4 medulloblastoma | 1.200 | 8.8e-05 |
| invasive ductal carcinoma | -1.800 | 2.5e-04 |
| lung cancer | -1.700 | 6.1e-04 |
| malignant mesothelioma | -1.200 | 2.0e-06 |
| osteosarcoma | -1.681 | 3.6e-05 |
MAGWIQAQQLQGDALRQMQVLYGQHFPIEVRHYLAQWIESQPWDAIDLDNPQDRAQATQLLEGLVQELQK 1 - 70 KAEHQVGEDGFLLKIKLGHYATQLQKTYDRCPLELVRCIRHILYNEQRLVREANNCSSPAGILVDAMSQK 71 - 140 HLQINQTFEELRLVTQDTENELKKLQQTQEYFIIQYQESLRIQAQFAQLAQLSPQERLSRETALQQKQVS 141 - 210 LEAWLQREAQTLQQYRVELAEKHQKTLQLLRKQQTIILDDELIQWKRRQQLAGNGGPPEGSLDVLQSWCE 211 - 280 KLAEIIWQNRQQIRRAEHLCQQLPIPGPVEEMLAEVNATITDIISALVTSTFIIEKQPPQVLKTQTKFAA 281 - 350 TVRLLVGGKLNVHMNPPQVKATIISEQQAKSLLKNENTRNECSGEILNNCCVMEYHQATGTLSAHFRNMS 351 - 420 LKRIKRADRRGAESVTEEKFTVLFESQFSVGSNELVFQVKTLSLPVVVIVHGSQDHNATATVLWDNAFAE 421 - 490 PGRVPFAVPDKVLWPQLCEALNMKFKAEVQSNRGLTKENLVFLAQKLFNNSSSHLEDYSGLSVSWSQFNR 491 - 560 ENLPGWNYTFWQWFDGVMEVLKKHHKPHWNDGAILGFVNKQQAHDLLINKPDGTFLLRFSDSEIGGITIA 561 - 630 WKFDSPERNLWNLKPFTTRDFSIRSLADRLGDLSYLIYVFPDRPKDEVFSKYYTPVLAKAVDGYVKPQIK 631 - 700 QVVPEFVNASADAGGSSATYMDQAPSPAVCPQAPYNMYPQNPDHVLDQDGEFDLDETMDVARHVEELLRR 701 - 770 PMDSLDSRLSPPAGLFTSARGSLS 771 - 794 //
